Antonino Magdalena, Marmo Paula, Freites Carlos Leandro, Quassollo Gonzalo Emiliano, Sánchez Maria Florencia, Lorenzo Alfredo, Bignante Elena Anahi
Instituto de Investigación Médica Mercedes y Martín Ferreyra, INIMEC-CONICET-Universidad Nacional de Córdoba, Córdoba, Argentina.
Centro de Microscopía y Nanoscopía, CEMINCO-CONICET-Universidad Nacional de Córdoba, Córdoba, Argentina.
Front Cell Dev Biol. 2022 Apr 4;10:852738. doi: 10.3389/fcell.2022.852738. eCollection 2022.
Alzheimer's disease (AD) is characterized by the deposition of aggregated species of amyloid beta (Aβ) in the brain, which leads to progressive cognitive deficits and dementia. Aβ is generated by the successive cleavage of the amyloid precursor protein (APP), first by β-site APP cleaving enzyme 1 (BACE1) and subsequently by the γ-secretase complex. Those conditions which enhace or reduce its clearance predispose to Aβ aggregation and the development of AD. studies have demonstrated that Aβ assemblies spark a feed-forward loop heightening Aβ production. However, the underlying mechanism remains unknown. Here, we show that oligomers and fibrils of Aβ enhance colocalization and physical interaction of APP and BACE1 in recycling endosomes of human neurons derived from induced pluripotent stem cells and other cell types, which leads to exacerbated amyloidogenic processing of APP and intracellular accumulation of Aβ42. In cells that are overexpressing the mutant forms of APP which are unable to bind Aβ or to activate Go protein, we have found that treatment with aggregated Aβ fails to increase colocalization of APP with BACE1 indicating that Aβ-APP/Go signaling is involved in this process. Moreover, inhibition of Gβγ subunit signaling with βARKct or gallein prevents Aβ-dependent interaction of APP and BACE1 in endosomes, β-processing of APP, and intracellular accumulation of Aβ42. Collectively, our findings uncover a signaling mechanism leading to a feed-forward loop of amyloidogenesis that might contribute to Aβ pathology in the early stages of AD and suggest that gallein could have therapeutic potential.
阿尔茨海默病(AD)的特征是大脑中β淀粉样蛋白(Aβ)聚集物的沉积,这会导致进行性认知缺陷和痴呆。Aβ由淀粉样前体蛋白(APP)的连续切割产生,首先由β位点APP切割酶1(BACE1)切割,随后由γ-分泌酶复合物切割。那些增强或降低其清除率的条件易导致Aβ聚集和AD的发展。研究表明,Aβ聚集体引发了一个前馈回路,提高了Aβ的产生。然而,其潜在机制仍然未知。在这里,我们表明,Aβ的寡聚体和原纤维增强了源自诱导多能干细胞和其他细胞类型的人类神经元再循环内体中APP和BACE1的共定位和物理相互作用,这导致APP的淀粉样生成加工加剧和Aβ42的细胞内积累。在过表达无法结合Aβ或激活Go蛋白的APP突变形式的细胞中,我们发现用聚集的Aβ处理不能增加APP与BACE1的共定位,表明Aβ-APP/Go信号通路参与了这一过程。此外,用βARKct或加兰他敏抑制Gβγ亚基信号通路可防止内体中APP与BACE1的Aβ依赖性相互作用、APP的β加工以及Aβ42的细胞内积累。总的来说,我们的发现揭示了一种导致淀粉样蛋白生成前馈回路的信号机制,这可能在AD早期阶段促成Aβ病理学,并表明加兰他敏可能具有治疗潜力。